Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/18273
Type
ArticleCopyright
Open access
Collections
- ENSP - Artigos de Periódicos [2298]
Metadata
Show full item record
GSK: PLEASE EXTEND PATENT POOL TO AIDS DRUGS
Affilliation
UNITAID. Genebra, Suiça
Fundação Oswaldo Cruz. Escola Nacional de Saúde Pública Sergio Arouca. Rio de Janeiro, RJ, Brasil
Fundação Oswaldo Cruz. Escola Nacional de Saúde Pública Sergio Arouca. Rio de Janeiro, RJ, Brasil
Abstract
As you state in your Feb 28 Editorial,1 GlaxoSmithKline's (GSK's) Chief Executive Officer Andrew Witty is to be commended for his announcement of GSK's medicines pricing practices in developing countries and in particular his proposal of a patent pool to allow research into neglected diseases by others than the patent holders. But he has to go further. He should also make GSK's patents on AIDS medicines available for the development of more affordable fixed-dose combinations for patients in poor countries.
Share